…
Epsilon Healthcare Limited, together with its subsidiaries, engages in the healthcare business in Australia. The company operates in three segments, Contract Development and Manufacturing Activities, Telehealth Medical Practice Services, and Pharmacy Services. It is involved in the healthcare and clinics operation; pharmaceutical contract development and manufacturing; development and manufacturing of active pharmaceutical ingredients and finished formulation; and provision of pharmacy services and patient care. The company was formerly known as THC Global Group Limited and changed its name to Epsilon Healthcare Limited in February 2021. Epsilon Healthcare Limited was incorporated in 2016 and is based in Southport, Australia.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Epsilon Healthcare Ltd operates residential aged-care facilities and related healthcare services in Australia and New Zealand, offering long-term care and support for older adults. Long-term growth drivers include demographic ageing, government funding for aged and community care, and potential scale benefits from operational consolidation; investors may find the company attractive for recurring revenue exposure to essential services and potential occupancy and efficiency improvements.
Key investment risks include changes to government funding or regulation, operational execution and staffing shortages that can affect care quality and occupancy, exposure to property valuation and market pricing, and any balance-sheet leverage that could limit flexibility.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -3.02M | -5.57M | -3.31M | -12.68M | -10.37M |
| Net income | -2.05M | -3.25M | -1.09M | -12.68M | -8.91M |
| Selling general administrative | - | 1.70M | 2.87M | 3.91M | 6.85M |
| Selling and marketing expenses | - | 0.20M | 0.21M | 0.34M | 0.42M |
| Gross profit | 2.25M | 4.17M | 4.81M | 1.34M | 2.06M |
| Reconciled depreciation | - | 1.41M | 1.48M | 1.86M | 1.56M |
| Ebit | -2.22M | -4.88M | -2.79M | -9.55M | -7.05M |
| Ebitda | -1.86M | -2.13M | -1.31M | -7.69M | -5.49M |
| Depreciation and amortization | 0.36M | 2.75M | 1.48M | 1.86M | 1.56M |
| Operating income | -2.22M | -4.19M | -2.42M | -9.55M | -7.05M |
| Other operating expenses | 11.61M | 7.73M | 7.59M | 16.80M | 15.00M |
| Interest expense | 1.26M | 1.15M | 0.52M | 0.58M | 0.80M |
| Tax provision | - | -0.13M | -2.22M | 0.00M | -1.46M |
| Interest income | - | 1.14M | 0.49M | 0.60M | 0.83M |
| Net interest income | - | -1.15M | -0.52M | -0.68M | -0.80M |
| Income tax expense | -0.97M | 2.33M | -2.22M | 0.82M | -1.46M |
| Total revenue | 9.39M | 5.60M | 6.65M | 7.11M | 5.50M |
| Total operating expenses | 4.47M | 6.31M | 5.75M | 11.03M | 11.56M |
| Cost of revenue | 7.14M | 1.43M | 1.84M | 5.78M | 3.44M |
| Total other income expense net | -0.80M | -1.39M | -0.89M | -2.31M | -0.07M |
| Net income from continuing ops | - | -5.49M | -1.09M | -12.68M | -8.91M |
| Net income applicable to common shares | - | -5.49M | -1.09M | -13.29M | -9.24M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 17.87M | 10.46M | 14.41M | 20.50M | 30.55M |
| Intangible assets | - | - | - | 0.00M | 0.50M |
| Other current assets | 0.30M | 0.19M | 0.03M | 0.76M | 0.71M |
| Total liab | 14.88M | 12.53M | 6.87M | 11.23M | 10.98M |
| Total stockholder equity | 2.99M | -2.08M | 7.54M | 9.27M | 19.57M |
| Other current liab | 0.34M | 0.23M | 0.54M | 0.74M | 1.09M |
| Common stock | 48.27M | - | - | 46.88M | 44.82M |
| Capital stock | - | 47.53M | 46.81M | 46.88M | 44.82M |
| Retained earnings | -51.66M | -53.59M | -48.10M | -48.97M | -35.97M |
| Other liab | - | - | - | 2.65M | 3.19M |
| Good will | - | - | - | 0.00M | 4.47M |
| Other assets | - | - | - | 0.12M | 0.13M |
| Cash | 0.24M | 1.57M | 0.34M | 0.86M | 2.34M |
| Total current liabilities | 4.61M | 11.50M | 6.37M | 7.93M | 7.14M |
| Current deferred revenue | 0.44M | - | - | 0.64M | 0.93M |
| Net debt | 13.92M | 6.29M | 2.95M | 2.34M | 1.99M |
| Short term debt | 0.58M | - | - | 2.54M | 3.67M |
| Short long term debt | - | 7.85M | 3.29M | 2.55M | 3.55M |
| Short long term debt total | 14.16M | - | - | 3.20M | 4.33M |
| Other stockholder equity | - | - | - | -0.61M | -0.75M |
| Property plant equipment | - | - | - | 15.62M | 17.48M |
| Total current assets | 5.27M | 3.69M | 2.09M | 4.76M | 7.81M |
| Long term investments | - | - | - | - | 0.13M |
| Net tangible assets | - | - | - | 9.88M | 14.44M |
| Net receivables | 3.52M | 0.90M | 1.13M | 3.15M | 2.16M |
| Inventory | 1.20M | 0.53M | - | 0.61M | 2.42M |
| Accounts payable | 3.26M | 2.59M | 1.20M | 4.65M | 2.38M |
| Accumulated other comprehensive income | 6.38M | - | - | 11.98M | 11.47M |
| Non currrent assets other | 0.44M | 0.07M | 0.07M | 0.12M | 0.13M |
| Non current assets total | 12.60M | 6.77M | 12.32M | 15.74M | 22.74M |
| Capital lease obligations | - | 0.03M | 0.16M | 0.65M | 0.78M |
| Long term debt total | - | - | - | 0.65M | 0.66M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -0.10M | -0.10M | -0.53M | -0.74M |
| Change to liabilities | - | - | - | 0.00M | 0.31M |
| Total cashflows from investing activities | 6.29M | -0.10M | -0.10M | -0.53M | -0.74M |
| Net borrowings | - | 4.13M | 0.49M | -1.28M | -0.93M |
| Total cash from financing activities | -4.48M | 4.73M | 0.34M | 1.61M | 1.47M |
| Net income | -2.05M | -3.25M | -1.09M | -12.68M | -9.24M |
| Change in cash | -1.32M | 1.22M | -0.47M | -1.47M | -4.63M |
| Begin period cash flow | 1.57M | 0.34M | 0.81M | 2.34M | 6.97M |
| End period cash flow | 0.24M | 1.57M | 0.34M | 0.86M | 2.34M |
| Total cash from operating activities | -3.13M | -3.41M | -0.70M | -2.57M | -5.43M |
| Issuance of capital stock | - | 0.72M | - | - | 2.45M |
| Depreciation | 0.36M | 2.75M | 0.00M | 1.86M | 1.09M |
| Other cashflows from investing activities | -0.24M | 0.00M | 0.00M | 0.00M | 0.01M |
| Change to inventory | - | - | - | - | -0.46M |
| Change to account receivables | - | - | 1.71M | - | -0.84M |
| Sale purchase of stock | - | 0.72M | 0.00M | 2.89M | 2.51M |
| Other cashflows from financing activities | -0.24M | 4.13M | -0.16M | -0.53M | -0.56M |
| Change to netincome | - | - | - | 8.24M | 3.66M |
| Capital expenditures | 0.17M | 0.10M | 0.10M | 0.53M | 0.75M |
| Change in working capital | - | 0.30M | 0.00M | 1.11M | 1.04M |
| Stock based compensation | - | - | 0.00M | - | - |
| Other non cash items | -1.43M | -2.91M | 0.38M | - | - |
| Free cash flow | -3.30M | -3.50M | -0.80M | -0.53M | -0.75M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
|
Stock Name
|
Change
(AUD) |
Price
(AUD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| EPN Epsilon Healthcare Ltd |
0.00 4.35% |
0.02 | - | - | 0.57 | 2.01 | 1.12 | 9.81 |
| AFP Aft Pharmaceuticals Ltd |
0.05 1.41% |
3.60 | 29.92 | 18.18 | 1.48 | 4.37 | 2.05 | 18.56 |
| VLS Vita Life Sciences Ltd |
0.09 3.42% |
2.72 | 13.50 | 42.73 | 1.52 | 2.62 | 1.19 | 7.17 |
| LGP Little Green Pharma Ltd |
0.01 16.67% |
0.07 | - | 10.00 | 0.64 | 0.60 | 1.25 | 19.47 |
| MVP Medical Developments International Ltd |
- -% |
0.44 | 40.00 | 166.67 | 1.06 | 0.79 | 0.57 | 7.45 |
Epsilon Healthcare Limited, together with its subsidiaries, engages in the healthcare business in Australia. The company operates in three segments, Contract Development and Manufacturing Activities, Telehealth Medical Practice Services, and Pharmacy Services. It is involved in the healthcare and clinics operation; pharmaceutical contract development and manufacturing; development and manufacturing of active pharmaceutical ingredients and finished formulation; and provision of pharmacy services and patient care. The company was formerly known as THC Global Group Limited and changed its name to Epsilon Healthcare Limited in February 2021. Epsilon Healthcare Limited was incorporated in 2016 and is based in Southport, Australia.
| Name | Title | Year Born |
|---|---|---|
| Mr. Sonny Didugu | Group COO & Joint Company Sec. | NA |
| Ms. Laura Harvey | Chief Operations Officer - Canada | NA |
| Ms. Diandra Phipps | Chief Operating Officer of Tetra Health | NA |
| Mr. Mark Audet | CFO & Joint Company Sec. | NA |
| Mr. Jim Barlow | Chief Agronomist and Regional Mang. of the Americas | NA |
| Mr. Xiao Cui | Executive Chairman | NA |
| Mr. Daniel Sanghera | Interim Chief Executive Officer | NA |
| Ms. Li Lin | Group Financial Controller | NA |
| Mr. Marcelo Mora | Company Secretary | NA |
| Mr. Xiao Cui | Executive Chairman | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.